Orlistat competitive inhibitor

Sep 28, 2011 · Orlistat or tetrahydrolipstatin is a competitive inhibitor of pancreatic lipase (PL) with β lactone cycle incorporated into a carbon skeleton. Jan 17, 2012 · Citations: 330 PDF Tools Share Abstract Orlistat, a weight-loss agent with a novel mechanism of action, recently was approved by the Food and Drug Administration for the treatment of obesity

2024-03-28
    Naltrexone inexpensive how much
  1. 1096/fasebj
  2. It was approved by the FDA for use in combination
  3. Last updated on Feb 24, 2023
  4. How do we study competitive inhibition
  5. All columbusserves
  6. Orlistat is an inhibitor of pancreatic lipase
  7. Common orlistat side effects are caused by its fat-blocking action
  8. Orlistat’s action does not require systemic absorption